HOME

TheInfoList



OR:

MedImmune, LLC was a wholly owned subsidiary of
AstraZeneca AstraZeneca plc () is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas includi ...
before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. Its main offices were located in
Gaithersburg, MD Gaithersburg ( ), officially the City of Gaithersburg, is a city in Montgomery County, Maryland, United States. At the time of the 2020 U.S. Census, Gaithersburg had a population of 69,657, making it the ninth-largest location in the state. Gai ...
,
Cambridge, UK Cambridge ( ) is a College town, university city and the county town in Cambridgeshire, England. It is located on the River Cam approximately north of London. As of the 2021 United Kingdom census, the population of Cambridge was 145,700. Cam ...
, and Mountain View, CA. It produced ''
Synagis Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for R ...
'', a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and ''
FluMist Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that is recommended for the prevention of influenza. It is an attenuated vaccine, unlike most influenza vaccines, which are inactivated vaccine ...
'', a
nasal spray Nasal sprays are used to deliver medications locally in the nasal cavities or systemically. They are used locally for conditions such as nasal congestion and allergic rhinitis. In some situations, the nasal delivery route is preferred for syst ...
influenza vaccine Influenza vaccines, also known as flu shots, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies f ...
introduced in 2004. MedImmune acquired ''FluMist'' when it purchased Aviron in 2002 for US$ 1.5 billion. ''FluMist'' sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006. ''FluMist'' was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market—young children who find injections objectionable. Sales of ''FluMist'' fell short of analysts' expectations for the first two years the drug was sold. ''FluMist'' was initially sold in a frozen form, which was difficult for doctors to store.
Medimmune Company Site

Flumist nasal flu vaccine - Official website
* Bishop, Tricia. "MedImmune loss in '05 quadruples shortfall from '04" Baltimore Sun. 3 February 2006. * Rosenwald, Michael S.

Washington Post. 3 February 2006.
MedImmune conducted successful
clinical trials Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dieta ...
for a new generation of ''FluMist'' needle-free vaccine, called CAIV-T, which was approved by the U.S. Food and Drug Administration (FDA) in 2007, and is now the form offered on the market.


History

Molecular Vaccines, Inc. was founded by Wayne T. Hockmeyer, David Mott, and Dr. James Young in 1988. In 1989, Molecular Vaccines, Inc changed its name to MedImmune, Inc. On April 23, 2007, it was announced MedImmune and
AstraZeneca AstraZeneca plc () is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas includi ...
entered into a definitive agreement under which AstraZeneca intended to acquire MedImmune in an all-cash transaction at US$ 58 per share, or about US$ 15.2 billion. On 19 June 2007 AstraZeneca completed the acquisition paying US$ 15.2 billion primarily for its drug development pipeline. Analysts have criticised the take-over, claiming that AstraZeneca paid too much. AstraZeneca chose to merge MedImmune with
Cambridge Antibody Technology Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using pha ...
, which it had acquired in 2006, creating a new biologics division under the MedImmune name. AstraZeneca presented the new MedImmune to investors on 7 December 2007. In June 2007, the
National Institutes of Health The National Institutes of Health, commonly referred to as NIH (with each letter pronounced individually), is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the lat ...
(NIH) began enrolling participants in a Phase 1 H5N1 study of an intranasal
influenza vaccine Influenza vaccines, also known as flu shots, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies f ...
candidate based on MedImmune's live, attenuated vaccine technology. MedImmune said it was making a significant, rapid response with a vaccine to the novel H1N1 variant of influenza, known as swine flu. In June 2009 it won a
Department of Health and Human Services The United States Department of Health and Human Services (HHS) is a cabinet-level executive branch department of the U.S. federal government created to protect the health of all Americans and providing essential human services. Its motto is ...
(HHS) contract, worth $90m. Under the contract with HHS, MedImmune will continue to make its seasonal FluMist vaccine and also develop a vaccine targeted specifically at the novel H1N1 virus. MedImmune then won a second contract to test its nasal spray flu technology as a viable treatment for the H1N1. MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine in September 2009.


Pipeline

MedImmune had over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer. Major phase III trials included: *
durvalumab Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ...
(anti-PD-L1) *
tremelimumab Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Tremelimumab was approved for unresectable hepatocellular carcinoma medical use in the United States in O ...
(anti-CTLA-4) *
moxetumomab pasudotox Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including ...
(anti-CD22) * benralizumab (anti-IL-5R) * tralokinumab (anti-IL-13) *
anifrolumab Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interfero ...
(anti-IFN-aR) * nirsevimab (anti-RSV)


See also

*
MedImmune, Inc. v. Genentech, Inc. ''MedImmune, Inc. v. Genentech, Inc.'', 549 U.S. 118 (2007), was a decision by the Supreme Court of the United States involving patent law.. It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genent ...


References and notes


External links


Flumist nasal flu vaccine - Official website
{{DEFAULTSORT:Medimmune Companies based in Gaithersburg, Maryland Biotechnology companies of the United States Health care companies based in Maryland Vaccine producers AstraZeneca Biotechnology companies established in 1988 Pharmaceutical companies established in 1988 2007 mergers and acquisitions American subsidiaries of foreign companies